Financial Reports 2018

MD&A 2018 – refiled with re-audited financial statements

Annual Report 2018

2018 was once again a year filled with strong scientific and clinical program development achievements for Prometic.

Quarterly Report 2018 Q3

Successful Type C meeting with FDA: agreement on proposed plan of action for RyplazimTM (plasminogen) manufacturing process along with Substantial reduction in R&D costs of up to $30 million.

Quarterly Report Q2 2018

Advanced multiple initiatives aimed at extending cash runway, including ongoing partnering discussions related to both PBI-4050 and RyplazimTM (plasminogen).

Quarterly Report Q1 2018

Prometic reports its 2018 first quarter highlights and financial results

Notice of Annual and Special Meeting of Shareholders and Management Information Circular March 22, 2018

Notice of Annual and Special Meeting of Shareholders and Management Information Circular March 22, 2018